Ally Bridge Group (NY) LLC Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0001822947
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 16 positions · Total reported value $87.04M · Top-10 concentration 83.4% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 86.5% · 11 new · 9 cut · 12 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +22.2% · vs SPY +7.4% · Prev Value $117.12M — last quarter positions weighted by this quarter price moves · ranking
In its Q4 2025 13F filing, Ally Bridge Group (NY) LLC disclosed 16 equity positions with a combined reported value of $87.04M. The filing implies a focused portfolio: its ten largest positions account for 83.4% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were REPL ($11.66M), ABVX ($9.44M), SLNO ($7.78M). By sector, the heaviest allocations are Health Care 83.0%, Other 17.0%. Versus the prior quarter, allocation shifted toward Health Care (+7.3pp) and away from Other (-7.3pp).
Versus the prior quarter, Ally Bridge Group (NY) LLC opened 11 new positions, trimmed 9 and fully exited 12, a turnover rate of 86.5% of positions. The portfolio's overlap with the prior quarter was 36% of names.
The largest new positions opened in Q4 2025 were ABVX ($9.44M), IVA ($6.97M), NERV ($6.66M).
Of the 12 positions fully exited versus the prior quarter, the largest were MDGL ($14.98M), ASND ($10.16M), LENZ ($8.17M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
Fully Exited (vs previous quarter)
- MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $14.98M
- ASND ASCENDIS PHARMA A/S · prev qtr: $10.16M
- LENZ LENZ THERAPEUTICS INC · prev qtr: $8.17M
- AMLX AMYLYX PHARMACEUTICALS INC · prev qtr: $5.94M
- MNPR MONOPAR THERAPEUTICS INC · prev qtr: $5.26M
- ARQT ARCUTIS BIOTHERAPEUTICS INC · prev qtr: $4.40M
- MNMD MIND MEDICINE MINDMED INC · prev qtr: $4.26M
- TARS TARSUS PHARMACEUTICALS INC · prev qtr: $4.21M
Insider Transactions (Form 4)
Latest Ally Bridge Group (NY) LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Ally Bridge Group (NY) LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 25 US equity positions with a combined value of $113.07M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-121984 (status: Approved), registered 2021-07-30
- Regulatory AUM (Form ADV): $218.95M as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 3 private funds, of which 3 hedge funds
Portfolio Structure
- 25 positions · $113.07M reported value (Q2 2026)
- Top 10 holdings = 70.5% of reported value
- Largest position: DFTX (DEFINIUM THERAPEUTICS F) at 16.6%
- Average position size: $4.52M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 11 new, 3 added, 9 reduced, 12 exited
- 2 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
1.20M | $11.66M | 13.40% | Reduce | |
| 2 |
|
70.00K | $9.44M | 10.85% | New | |
| 3 |
|
168.03K | $7.78M | 8.94% | Reduce | |
| 4 |
|
1.10M | $7.59M | 8.72% | Add | |
| 5 |
|
1.71M | $7.01M | 8.05% | Reduce | |
| 6 |
|
1.50M | $6.97M | 8.01% | New | |
| 7 |
|
1.66M | $6.66M | 7.65% | New | |
| 8 |
|
19.88K | $5.86M | 6.73% | Reduce | |
| 9 |
|
195.00K | $4.84M | 5.56% | New | |
| 10 |
|
200.00K | $4.79M | 5.50% | New | |
| 11 |
|
397.89K | $3.00M | 3.45% | Reduce | |
| 12 |
|
1.78M | $2.91M | 3.34% | New | |
| 13 |
|
457.13K | $2.51M | 2.89% | Reduce | |
| 14 |
|
413.62K | $2.33M | 2.68% | Reduce | |
| 15 |
|
817.94K | $1.98M | 2.27% | Hold | |
| 16 |
|
249.34K | $1.70M | 1.96% | Reduce | |
FAQ
What did Ally Bridge Group (NY) LLC buy in 2025-Q4?
In its 2025-Q4 13F filing, Ally Bridge Group (NY) LLC reported 16 equity positions worth $87.04M in aggregate; its largest disclosed positions were REPL ($11.66M), ABVX ($9.44M), SLNO ($7.78M).
How large is Ally Bridge Group (NY) LLC's portfolio?
Ally Bridge Group (NY) LLC reported $87.04M of long equity holdings across 16 positions as of 2025-Q4. Top-10 holdings account for 83.4% of reported value.
What is Ally Bridge Group (NY) LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.